Novartis forms alliance with Bristol-Myers

Novartis signs deal with US group Keystone

Swiss healthcare group, Novartis, has formed an alliance with the United States firm, Bristol-Myers Squibb, to develop and promote Novartis's new irritable bowel syndrome (IBS) treatment, Zelmac.

This content was published on October 18, 2000 - 10:06

The drug, which Novartis intends to launch in the US in the first half of next year, pending approval by the US regulatory authorities, is the main focus of the company's promotion drive in 2001.

The US market is considered to be a key target for the new treatment.

The alliance, which excludes Japan, will promote Zelmac to doctors and strengthen Novartis' efforts to educate consumers about IBS.

Novartis said the ailment affects millions of people but its symptoms are often not clearly defined or understood.

The two firms will also collaborate in the development of two Bristol-Myers immune modulating compounds.

swissinfo with agencies

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.